Axsome Therapeutics, Inc. (AXSM) financial statements (2020 and earlier)

Company profile

Business Address 200 BROADWAY, 3RD FLOOR
NEW YORK, NY 10038
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments44143437
Cash and cash equivalents44143437
Other undisclosed current assets1111
Total current assets:44153538
Noncurrent Assets
Property, plant and equipment0000
Other noncurrent assets0000
Total noncurrent assets:0000
TOTAL ASSETS:44153638
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11545
Accounts payable9434
Accrued liabilities1101
Employee-related liabilities1111
Debt1330
Other undisclosed current liabilities7242
Total current liabilities:1911127
Noncurrent Liabilities
Long-term debt and lease obligation19479
Long-term debt, excluding current maturities19479
Total noncurrent liabilities:19479
Total liabilities:38141917
Stockholders' equity
Stockholders' equity attributable to parent711722
Common stock0000
Additional paid in capital1581089369
Accumulated deficit(151)(108)(77)(48)
Total stockholders' equity:711722
TOTAL LIABILITIES AND EQUITY:44153638

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
Operating expenses(52)(33)(27)(28)
Operating loss:(52)(33)(27)(28)
Nonoperating expense
(Investment Income, Nonoperating)
(1)(1)(1)(0)
Loss from continuing operations before income taxes:(53)(34)(29)(28)
Other undisclosed loss from continuing operations(0)   
Loss before gain (loss) on sale of properties:(54)(34)(29)(28)
Other undisclosed net income03  
Net loss:(53)(31)(29)(28)
Other undisclosed net income (loss) attributable to parent0 (0)0
Net loss available to common stockholders, diluted:(53)(31)(29)(27)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
Net loss:(53)(31)(29)(28)
Comprehensive loss, net of tax, attributable to parent:(53)(31)(29)(28)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: